DexCom, Inc. DXCM
Strong Medical Devices & Diagnostics sector · Continuous glucose monitors — recurring sensor revenue as diabetes care goes wearable.
DexCom, Inc. (DXCM) is an established Medical Devices & Diagnostics company, graded Strong on FrontierLab's evidence-based quality rubric (data as of 2026-10-05). Revenue grew 15.5% year-over-year at a 62.5% gross margin. Gross-profits-to-assets is 0.48; Rule of 40 is 38.4. Net share issuance -4% YoY (buying back shares). No risk flags are currently noted. Analyst mix: 31 buy / 5 hold / 0 sell. Track record: 55% of Strong-graded names beat the S&P over 63 sessions (95% CI 38–72%, N=29). Median excess vs the S&P was +2.2%.
These sentences are generated from the day's data by deterministic templates.
Key quality signals
| Revenue growth (YoY) | 15.5% |
|---|---|
| Gross margin | 62.5% |
| Gross profits / assets | 0.48 |
| Rule of 40 | 38.4 |
| Net margin | 22.9% |
| Cash runway (months) | — |
| PEG | 0.4 |
| Price / sales | 6.5 |
Quality checklist
Each line is one quality test behind the grade — ✓ passed · ~ borderline · ✗ failed. Hover a metric in the tables below for what it means.
- ~ Revenue growth — 15.5% (pass ≥ 20%)
- ✓ Gross profits / assets — 0.48 (pass ≥ 0.33)
- · Rule of 40 — 38.4 (context — graded for software only)
- ✓ Gross margin — 62.5% (pass ≥ 60% · Medical Devices & Diagnostics)
- ✓ Cash generation
- ✓ Share dilution — -4%
- ~ Competitive moat — Narrow
- ✓ Market size (TAM) — Large
Grade history
Graded Strong since 2026-06-10 — no grade changes recorded yet.
How have Strong-graded names performed?
The forward returns of all Strong-graded names since each grade was recorded — the bucket this name currently sits in, not a forecast of this individual stock.
| Window | Forward record vs the S&P | Median |
|---|---|---|
| ~1 month | 50% of Strong-graded names beat the S&P over 21 sessions (95% CI 33–67%, N=30). | Median excess vs the S&P was +0.9%. |
| ~3 months | 55% of Strong-graded names beat the S&P over 63 sessions (95% CI 38–72%, N=29). | Median excess vs the S&P was +2.2%. |
| ~6 months | building — 46 more sessions needed | |
Scope: these are forward returns vs the S&P among names still covered at each horizon's end, within the curated universe — not a survivorship-clean whole-market backtest. Names later dropped from coverage are counted as attrition (not hidden), and single-session moves beyond ±300% are treated as split/data artifacts and excluded. How this is measured → · Full track record →
How it compares
Coarse same-sector, same-stage context — not a percentile or rank. GP/A is graded on its absolute level, not position.
Fundamentals
| Market cap | $32.21B |
|---|---|
| Stage | Established |
| Share issuance (YoY) | -4% · buying back shares |
| Moat | Narrow |
| TAM | LARGE |
| P/E (trailing) | 33.7 |
| EPS (trailing) | $2.53 |
| Burn multiple | — |
| Gross-margin trend (pts) | 3.7 |
| Cash / assets | 0.3 |
| Accruals (%) | -10.9% |
| Net debt / EBITDA | 0.2 |
| Statements as of | Q2 FY2026 · filed 2026-07-30 |
Momentum context — describes the past, not a signal
Low reached Nov 10, 2025 · high reached Aug 21, 2026 — by daily close.
| Price | $85.36 (as of 2026-10-02) |
|---|---|
| Last session move | — |
| % off 52-wk high | -7.8% |
| RSI (14) | 44 |
| Relative volume | 0.5× |
Insider activity (90 days)
| Cluster buyers | 0 |
|---|---|
| Sellers | 7 |
Insider selling is routine diversification, not a bearish signal.
Analyst mix
| Strong buy | 15 |
|---|---|
| Buy | 16 |
| Hold | 5 |
| Sell | 0 |
| Strong sell | 0 |
Ratings are context, not a price target. "Momentum" = how the mix changed over recent weeks, not a forecast.
From the headlines
DexCom shows strong growth in CGM market with positive analyst outlook; Medtronic acquisition interest waning.
- DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care
- DexCom (NASDAQ:DXCM): Strong Growth Paired With a High-Quality Technical Setup
- RBC Capital Maintains Outperform on DexCom, Raises Price Target to $105
AI take — daily, AI-generated
AI leans positive
Exceptional PEG of 0.4 with 15.5% growth and shrinking dilution is a textbook buy signal, though the low retail sentiment (47%) hints the market hasn't fully priced in the opportunity.
Generated by an AI model from the day's news — an opinion for context only. Not financial advice, not a recommendation, and not a price target.
Similar Medical Devices & Diagnostics names
← All Medical Devices & Diagnostics names · Open DXCM in the interactive screener →
Data as of 2026-10-05 08:19 (end-of-day). How grades are computed →